Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention First Defense, the most common co-covered peer. Damien Leonard appears in 1 tracked Biotech story from March 4, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention First Defense, the most common co-covered peer. Damien Leonard appears in 1 tracked Biotech story from March 4, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Damien Leonard. Shared-story counts are live from our verified record — not editorial picks.
Financial Disclosure
ImmuCell releases unaudited FY2025 results; Pinetree Capital releases audited results.
Technical Breakout
ICCC stock price crosses above the 200-day moving average.
Fiscal Year End
ImmuCell concludes its 2025 fiscal year operations.
ImmuCell (ICCC) reported its unaudited financial results for the full year 2025, reflecting a period of manufacturing expansion and sustained demand for its FirstDefense product line. Concurrently, major investor Pinetree Capital Ltd. announced its own audited results and a new director appointment, signaling continued strategic oversight of its animal health portfolio.
Damien Leonard is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
